Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra in Refractory Hemochromatosis Rheumatism
NCT02263638Phase 2Terminated
- Sponsor
- CHU Rennes
- Start
- Feb 2015
- Primary completion
- Sep 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anakinra in hemochromatosis (HH), sponsored by CHU Rennes. Primary endpoint: Rate of patients with improvement of joint pain at 15 days. Started Feb 2015; status: terminated.
02
Drugs
anakinra
03
Conditions
hemochromatosis (HH)
Beyond the preview
Go deeper on NCT02263638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02263638.